

# Cancer Prone Disease Section

## Mini Review

## Ataxia telangiectasia

Nancy Uhrhammer, Jacques-Olivier Bay, Richard A Gatti

Centre Jean-Perrin, BP 392, 63000 Clermont-Ferrand, France (NU, JOB, RAG)

Published in Atlas Database: October 2002

Online updated version : <http://AtlasGeneticsOncology.org/Kprones/ataxia.html>  
DOI: 10.4267/2042/37940

This article is an update of :

Uhrhammer N, Bay JO, Gatti RA. Ataxia telangiectasia. *Atlas Genet Cytogenet Oncol Haematol.*1999;3(4):209-211.  
Huret JL. Ataxia telangiectasia. *Atlas Genet Cytogenet Oncol Haematol.*1998;2(4):153-154.

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.  
© 2003 *Atlas of Genetics and Cytogenetics in Oncology and Haematology*

### Identity

#### Alias

Louis-Bar syndrome

#### Note

See also, in Deep Insight section: Ataxia-Telangiectasia and variants.

#### Inheritance

Autosomal recessive; frequency is about 1 to 2.5/105 newborns; heterozygotes are estimated to be 1% of the general population; founder effect are found in some isolated population.

### Clinics

#### Note

Ataxia telangiectasia is a chromosome instability syndrome with cerebellar degeneration, immunodeficiency, and an increased risk of cancers; A-T cells are defective in recognizing double-strand DNA damage to signal for repair.

#### Phenotype and clinics

- Onset of the disease is often noted during the second year of life: there is progressive cerebellar ataxia (initially truncal, with further peripheral extension); ataxia is a constant feature in this disease; oculomotor apraxia, dysarthria, and dystonia; leading to muscular atrophy.
- Telangiectasia: facial region exposed to sunlight, and eyes (conjunctiva).
- Combined immunodeficiency (in 70%): thymus hypoplasia, and IgG2 and 4, IgA, IgE deficiency.
- Other features: growth retardation; hypogonadism; occasionally diabetes mellitus.

#### Neoplastic risk

- Risk of cancers is X 100, consisting mainly of T-cell malignancies (a 70-fold and 250-fold increased risk and B-cell malignancies, but not myeloid leukemia; carcinomas of the skin, ovary, breast, and stomach have also been described.
- Cancer treatment is complicated by radiation- and chemo-sensitivity.

#### Evolution

Progressive cerebellar degeneration: patients are usually in a wheelchair by the age of ten.


#### Prognosis

- Respiratory infection is the common cause of death, with cancer being the second most common.
- Survival is often into fourth decade today where optimal medical care is available.

### Cytogenetics

#### Inborn conditions

- Spontaneous chromatid/chromosome breaks, triradials, quadriradials (less prominent phenomenon than in Fanconi anaemia); telomeric associations.
- The best diagnosis test is on the (pathognomonic) highly elevated level (10% of mitoses) of inv(7)(p14q35), t(14;14)(q11;q32), and other non clonal stable chromosome rearrangements involving 2p12, 7p14, 7q35, 14q11, 14q32, and 22q11 (illegitimate recombinations between immunoglobulin superfamily genes Ig and TCR); normal level of those rearrangements are: 1/500 (inv(14)), 1/200 (t(7;14)), 1/10 000 (inv(7)).



Sporadic (rows 1 and 2) and clonal (row 3) rearrangements in ataxia telangiectasia (R- banding). Row 1, from left to right:  $inv(7)(p14q35)$ ,  $t(7;7)(p14;q35)$ ,  $t(14;14)(q11;q32)$ ,  $inv(14)(q11q32)$ ; Row 2, from left to right:  $t(7;14)(p14;q11)$ ,  $t(7;14)(q35;q11)$ ,  $t(7;14)(p14;q32)$ ,  $t(7;14)(q35;q32)$ ; Row 3, from left to right:  $inv(14)(q11;q32)$ ,  $t(X;14)(q28;q11)$  (note the late replicating X on the left),  $t(14;14)(q11;q32)$  - Courtesy Alain Aurias (modified figure reprinted from *Médecine/Sciences* 1986; 2: 298-303., by permission of the publisher Masson).

- Clonal rearrangements further occur in 10% of patients, but without manifestation of malignancy:  $t(14;14)$ ,  $inv(14)$ , or  $t(X;14)$ .

### Cytogenetics of cancer

Clonal rearrangements in T-cell ALL and T-PLL (prolymphocytic leukaemia) in AT patients are complex, with the frequent involvement of  $t(14;14)(q11;q32)(q11;q32)$ , or  $t(X;14)(q28;q11)$ , implicating the genes *TCL1* or *MTCP1* respectively, as is found in T-PLL in non-AT patients.

### Other findings

#### Note

- High sensitivity to ionizing radiations and to radiomimetic drugs (diagnostic may in part be based on the hypersensitivity of AT lymphocytes to killing by gamma irradiation); cell irradiation does not inhibit S phase (DNA synthesis): this is quite pathognomonic of AT, and shows that G1 checkpoint is deficient; there is a lack of P53, GADD45 and P21 induction, and a fall in radiation-induced apoptosis; P53 phosphorylation at ser15 is deficient.

- Lengthening of the cell cycle.

- Difficult to grow cells with phytohemagglutinin: karyotypes should be performed with interleukine 2 in 4 days cultures.

- Other: increased level of serum alpha-fetoprotein.

### Genes involved and proteins

#### ATM (Ataxia telangiectasia mutated)

is responsible for the vast majority of A-T cases.

#### Location

11q22-q23.1

#### DNA/RNA


Description: 66 exons spanning 184 kb of genomic DNA.

#### Protein

Description: 3056 amino acids; 350 kDa; contains a PI 3-kinase-like domain.

Localisation: Mostly in the nucleus in replicating cells, cytoplasm in differentiating cells.

Function: Mediates cell cycle arrest in response to ionizing radiation through the phosphorylation of targets including p53, cAbl, BRCA1, H2AX, IκB-alpha and chk1.



ATM (11q22.3) in normal cells: PAC 891P24 - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics.

### Mutations

Germinal: Various types of mutations, dispersed throughout the gene, and therefore most patients are compound heterozygotes; however, most mutations appear to inactivate the ATM protein by truncation, large deletions, or annulation of initiation or termination. Missense mutations have been described in breast cancer patients, but do not seem to contribute to ataxia-telangiectasia.

## To be noted

### Note

- Heterozygote cancer risk: the relative risk of breast cancer in A-T heterozygote women has been estimated through epidemiological studies to be 3.9 (CI 2.1-7.1), and through haplotype analysis to be 3.32 (CI 1.75-6.38); since the A-T heterozygote frequency is about 1%, 2-4% of breast cancer cases may be due to ATM heterozygosity; the risk of other types of cancer in A-T heterozygotes is low.
- The A-T variant Nijmegen breakage syndrome does not involve the same gene.

## References

Aurias A, Croquette MF, Nuyts JP, Griscelli C, Dutrillaux B. New data on clonal anomalies of chromosome 14 in ataxia telangiectasia: tct(14;14) and inv(14). *Hum Genet.* 1986 Jan;72(1):22-4

Aurias A, Dutrillaux B. Probable involvement of immunoglobulin superfamily genes in most recurrent chromosomal rearrangements from ataxia telangiectasia. *Hum Genet.* 1986 Mar;72(3):210-4

McKinnon PJ. Ataxia-telangiectasia: an inherited disorder of ionizing-radiation sensitivity in man. Progress in the elucidation of the underlying biochemical defect. *Hum Genet.* 1987 Mar;75(3):197-208

Stern MH, Zhang FR, Griscelli C, Thomas G, Aurias A. Molecular characterization of different ataxia telangiectasia T-cell clones. I. A common breakpoint at the 14q11.2 band splits the T-cell receptor alpha-chain gene. *Hum Genet.* 1988 Jan;78(1):33-6

Stern MH, Zhang FR, Thomas G, Griscelli C, Aurias A. Molecular characterization of ataxia telangiectasia T cell clones. III. Mapping the 14q32.1 distal breakpoint. *Hum Genet.* 1988 Dec;81(1):18-22

Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. *N Engl J Med.* 1991 Dec 26;325(26):1831-6

Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS, Shiloh Y, Rotman G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. *Hum Mol Genet.* 1995 Nov;4(11):2025-32

Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D, Wynshaw-Boris A. Atm-deficient mice: a paradigm of ataxia telangiectasia. *Cell.* 1996 Jul 12;86(1):159-71

Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. *Blood.* 1996 Jan 15;87(2):423-38

Barlow C, Brown KD, Deng CX, Tagle DA, Wynshaw-Boris A. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. *Nat Genet.* 1997 Dec;17(4):453-6

Platzer M, Rotman G, Bauer D, Uziel T, Savitsky K, Bar-Shira A, Gilad S, Shiloh Y, Rosenthal A. Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic DNA containing the entire ATM gene. *Genome Res.* 1997 Jun;7(6):592-605

Westphal CH. Cell-cycle signaling: Atm displays its many talents. *Curr Biol.* 1997 Dec 1;7(12):R789-92

Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. *Am J Hum Genet.* 2000 Feb;66(2):494-500

Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. *J Biol Chem.* 2001 Nov 9;276(45):42462-7

---

*This article should be referenced as such:*

Uhrhammer N, Bay JO, Gatti RA. Ataxia telangiectasia. *Atlas Genet Cytogenet Oncol Haematol.* 2003; 7(1):54-56.

---